Pet Net Pharmaceutical Service

Ortho-McNeil-Janssen Pharmaceuticals offers a range of health care products for the treatment of several infectious diseases, as well as pain management. The company s sister concern Ortho-McNeil, which serves primary care hospitals and other care facilities. Ortho-McNeil s products are available under the DURAGESIC, LEVAQUIN, FLOXIN, NIZORAL and PROPULSID brads. The company provides injections, shampoos, caplets, tablets and capsules. Ortho-McNeil offers the ACIPHEX product, which is used of the treatment of heartburn and other symptoms associated with acid reflux disease. The company additionally provides the DORIBAX product for patients with gram negative infections. Ortho-McNeil undertakes several research and development activities.

Amneal Pharmaceuticals is a leading provider of essential medicines, committed to making health possible through a broad portfolio of approximately 280 generic and specialty pharmaceuticals, as well as biosimilars. The company emphasizes innovation in drug development, particularly in providing first-to-file and first-to-market complex medicines, while also actively participating in initiatives to improve patient care, such as support for those affected by Parkinson's disease and increasing access to Naloxone nasal spray. Headquartered in Piscataway, NJ, Amneal fosters a culture that inspires its workforce to rise, lead, and succeed in their mission to enhance patient outcomes. Their dedication to corporate responsibility includes a focus on patient assistance programs and community philanthropy, further solidifying their commitment to health and wellness. Generated from the website

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company based in Berkeley Heights, NJ, focused on developing innovative cancer medicines through the exploration of cell cycle transcriptional regulation, epigenetics, and mitosis biology. The company aims to address oncology and hematology indications by building a diversified pipeline of novel drug candidates that target mechanisms of resistance in cancer cells. As a pioneer in cell cycle biology, Cyclacel is dedicated to reactivating the body's own cell death mechanisms to combat cancer. Currently, the company has two orally available programs in clinical development: Fadraciclib, a CDK2 and CDK9 inhibitor, and Plogosertib, a PLK1 inhibitor. Generated from the website